Royalty Pharma/$RPRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Ticker
$RPRX
Sector
Primary listing
Employees
-
Headquarters
Website
Royalty Pharma Metrics
BasicAdvanced
$16B
22.01
$1.75
0.47
$0.87
2.28%
Price and volume
Market cap
$16B
Beta
0.47
52-week high
$41.24
52-week low
$24.05
Average daily volume
3.1M
Dividend rate
$0.87
Financial strength
Current ratio
3.484
Quick ratio
3.474
Long term debt to equity
89.209
Total debt to equity
93.191
Dividend payout ratio (TTM)
49.33%
Interest coverage (TTM)
5.59%
Profitability
Gross margin (TTM)
106.59%
Net profit margin (TTM)
32.55%
Operating margin (TTM)
66.48%
Management effectiveness
Return on assets (TTM)
5.22%
Return on equity (TTM)
13.11%
Valuation
Price to earnings (TTM)
22.013
Price to revenue (TTM)
7.123
Price to book
2.58
Price to tangible book (TTM)
3.02
Price to free cash flow (TTM)
17.717
Free cash flow yield (TTM)
5.64%
Free cash flow per share (TTM)
2.176
Dividend yield (TTM)
2.26%
Forward dividend yield
2.28%
Growth
Revenue change (TTM)
3.70%
Earnings per share change (TTM)
-31.41%
3-year revenue growth (CAGR)
1.50%
3-year earnings per share growth (CAGR)
23.44%
3-year dividend per share growth (CAGR)
5.54%
What the Analysts think about Royalty Pharma
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Bulls say / Bears say
Royalty Pharma's acquisition of Amgen’s Imdelltra royalty interest for up to $950 million gives the company access to a fast-growing small cell lung cancer therapy projected to generate more than $2.8 billion in annual sales by 2035, broadening and strengthening its position in oncology ([Reuters] ([turn2news12])).
The $1.1 billion internalization of RP Management and the approval of a $3 billion share buyback program will simplify Royalty Pharma’s corporate structure and are expected to deliver over $100 million in yearly cash savings by 2026, growing to $175 million by 2030. These moves will return capital to shareholders and enhance corporate governance ([Reuters] ([turn11search8])).
Morgan Stanley reinstated an Overweight rating on Royalty Pharma in May 2025, setting a $51 price target. The move reflects analyst confidence in Royalty Pharma's diversified royalty model and above-average growth prospects, indicating potential for further stock gains at current levels near its 52-week high ([Investing.com] ([turn5search2])).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Royalty Pharma Financial Performance
Revenues and expenses
Royalty Pharma Earnings Performance
Company profitability
Royalty Pharma News
AllArticlesVideos
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
MarketBeat1 week ago
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Reuters2 months ago
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Royalty Pharma stock?
Royalty Pharma (RPRX) has a market cap of $16B as of November 09, 2025.
What is the P/E ratio for Royalty Pharma stock?
The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 22.01 as of November 09, 2025.
Does Royalty Pharma stock pay dividends?
Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of November 09, 2025, the dividend rate is $0.87 and the yield is 2.28%. Royalty Pharma has a payout ratio of 49.33% on a trailing twelve-month basis.
When is the next Royalty Pharma dividend payment date?
The next Royalty Pharma (RPRX) dividend payment is scheduled for December 10, 2025.
What is the beta indicator for Royalty Pharma?
Royalty Pharma (RPRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.